Raiffeisen Bank International’s BioMarin Pharmaceuticals BMRN Stock Holding History

Raiffeisen Bank International’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$767K	Hold	14,000	–	–	0.01%	412
2025 Q4	$826K	Sell	14,000 -14,706	-51%	-$801K	0.01%	379
2025 Q3	$1.55M	Buy	28,706 +5,226	+22%	+$299K	0.02%	270
2025 Q2	$1.27M	Buy	23,480 +1,651	+8%	+$97.2K	0.02%	253
2025 Q1	$1.56M	Buy	21,829 +6,171	+39%	+$415K	0.02%	236
2024 Q4	$1.03M	Buy	+15,658	New	+$1.05M	0.02%	270

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raiffeisen Bank International's BMRN Position: Q1 2026 in Review

Raiffeisen Bank International held its BioMarin Pharmaceuticals (BMRN) position steady in Q1 2026 at 14,000 shares worth $767K. The position accounts for 0.01% of the portfolio, ranked #412.

Raiffeisen Bank International first reported a position in BMRN in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.56M in Q1 2025. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Raiffeisen Bank International held 14,000 shares of BioMarin Pharmaceuticals worth $767K as of Q1 2026.
Raiffeisen Bank International left its BioMarin Pharmaceuticals share count unchanged in Q1 2026.
BioMarin Pharmaceuticals made up 0.01% of Raiffeisen Bank International's portfolio in Q1 2026, its #412 holding.
Raiffeisen Bank International first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
Raiffeisen Bank International's BioMarin Pharmaceuticals position peaked at $1.56M in Q1 2025.
555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Raiffeisen Bank International's 13F filing for Q1 2026, filed 24 Apr 2026.